case_images: PMC9254302_01
case_images: Position in a pan-cancer dimension reduction plot generated with the http://www.epidip.org tool.
case_images: pha-0107-0433-g01.jpg
case_images: PMC9254302_01_pha-0107-0433-g01.jpg
case_images: F1
case_images: DNA methylome did not match to any of the defined glioblastoma, IDH wildtype, subgroups, and lacked the prototypical +7/-10 chromosomal signature of glioblastoma, IDH wildtype; highest classifier v11b4 calibrated scores for glioblastoma, IDH wildtype (0.38, no match; cut-off >=0.9), subclass RTK I (0.25). Dimension reduction showed some similarity to glioblastoma, IDH wildtype but did not fall into any of the distinct clusters (Fig. 1).
case_images: Schematic representation of the NTRK3-ARHGEF7 fusion.
case_images: pha-0107-0433-g02.jpg
case_images: PMC9254302_01_pha-0107-0433-g02.jpg
case_images: F2
case_images: Targeted RNA sequencing identified an NTRK3 (exon 15) - ARHGEF7 (exon 17) fusion (Fig. 2).
case_images: T1-weighted (upper panel) and T2-weighted MRI of the brain (gadolinium administration) before and after larotrectinib treatment.
case_images: pha-0107-0433-g03.jpg
case_images: PMC9254302_01_pha-0107-0433-g03.jpg
case_images: F3
case_images: Six weeks after treatment initiation, a brain MRI revealed partial response according to RANO criteria (Fig. 3).
case_images: Timeline of interventions and treatments.
case_images: pha-0107-0433-g04.jpg
case_images: PMC9254302_01_pha-0107-0433-g04.jpg
case_images: F4
case_images: Sustained clinical benefit was preserved 2 months after stop of larotrectinib and 6 months after diagnosis (Fig. 4).